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Abstract. For sinus diseases, targeted delivery at affected sinonasal sites can be
the key to improve efficacy of topical sprays as a nasal therapeutic. Considering
that ostiomeatal complex (OMC) is the mucociliary drainage pathway and airflow
exchange corridor between the main airway and the frontal, maxillary, and anterior
ethmoid sinuses, we have identified sprayer techniques that are more effective in tar-
geting OMC, along with the sinus cavities. Nasal airflow and drug transport have been
numerically simulated in five CT-based sinonasal airway reconstructions, drawn from
pre-operative chronic rhinosinusitis patients. In each digital model, we applied two
different spray orientations at 5-mm insertion: (a) package insert-based direction – an
upright spray axis with subject-head inclined slightly forward (22.5◦), (b) line-of-sight
(LoS) – with spray axis directed at OMC and through centroid of visible OMC’s pro-
jection on the view-plane for best OMC-sighting. LoS protocol registered an average
8-fold higher targeted delivery, with the finding supported by both parametric t-test
and non-parametric Wilcoxon signed rank test. Simulated dose in two representative
models was validated by in vitro spray experiments in 3D-printed replicas. Finally,
observational LoS scores, based on how much of OMC was visible from nostrils, cor-
related well with the ratio of the projected area of the OMC on the nostril plane to
the area of the nostril plane itself. While these CFD-based findings can eventually
translate into new personalized spray usage instructions and change the standard-of-
care for nasal treatments, this study also demonstrates how use of relatively simple
engineering tools can revolutionize everyday healthcare.
Keywords: Respiratory therapeutics; topical drug delivery; nasal airflow; computational
fluid dynamics
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1. Introduction
Inside our nose, there is a complicated mechanistic assortment (see Figure 1) comprising
the main nasal passage, the mucociliary hairs and drainage fluid along its internal walls,
and the adjoining sinus cavities of various shapes and sizes.1,2 Occlusion of these sinus
chambers is a common symptom associated with many nasal ailments, such as chronic
rhinosinusitis.3 While surgical treatments essentially focus on enlarging the opening to
the sinus chambers, such procedures can be cost-intensive. As a first line of treatment,
the physicians often recommend the use of topical sprays,4,5 with the rationale that
these topical drugs will reduce inflammation at the diseased sites and assist in releasing
the occlusion. While such sprays do rank amongst the most commonly used therapeutics
for nasal conditions, the efficacy of the drugs can be highly patient-specific and there is
no well-defined protocol to ensure that specific dosage would reach the internal target
sites inside the nasal passage.
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Figure 1: (a) Anatomic features inside a human nose, as viewed on a
cut-away. (b) Position of the cut-away section, marked by dark line. (c)
Representative coronal section, with the main nasal passage shown in
lighter color.
Transport of topical drugs
inside the nose encounters a num-
ber of challenges, namely the tor-
tuosity of the complicated air-
way geometry, the sweeping ef-
fect of the mucociliary drainage,
and lack of consistent usage pro-
tocol for the medical device used
for drug application, primarily
owing to the inter-subject varia-
tions in the internal anatomic ge-
ometry. While tracking the tra-
jectories for topical nasal drug
transport in real human sub-
jects is still improbable, with
advancement of computational
tools, there has been a significant
push to obtain numerically sim-
ulated predictions of respiratory
flow physics and transport therein; see e.g.6–8 Of interest are nasal spray simulation
studies on in silico models, re-constructed from medical imaging, to measure drug deliv-
ery along the nasal passages,9 in the sinuses,10 and on the effects of surgical alternations
of the anatomy for the nasal airflow11–13 as well as for topical transport of drugs.14–16
The latter addresses the role of airway channel geometry on airflow-particle interactions.
Also, while using medical devices like sprayers, which are inserted at the nostril, the
anterior airway geometry gets altered. To simplify the situation a bit, computational
results10 suggest that such initial perturbation do not significantly change or adversely
affect the eventual drug deposits at the diseased sites much. There is, however, a distinct
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lack in articulating a proper guidance system on what could be the “best” way to use
the commercially available sprayers, to ensure maximal drug delivery for the patients.
First, numerical studies often do not use a realistic spray particle size distribution in
the simulations. Focusing on specific particle sizes can be resourceful in studying the
detailed nuances of transport characteristics in that size range; however that somewhat
limits the applicability of the subsequent findings while predicting the performance of
real sprays. Secondly, the inter-subject anatomic variations also render it difficult to
figure out a generic spray orientation that can work for all, to ensure maximal delivery
of drugs at the target diseased locations inside the nose.
In this study, we have numerically tracked the transport of therapeutic particulates
from nasal sprays via inhaled airflow. The computational fluid dynamics (CFD) models
of particle transport and the in silico prediction of their deposition sites along the nasal
airway walls have been compared with in vitro spray experiments in 3D-printed solid
replicates of the same anatomic models. We have proposed a new strategy of nasal spray
usage and the recommendation is supported by a significant improvement in target site
particle delivery (TSPD), when compared to the prevalent spray usage techniques. The
study also opens up the potential of using CFD as a tool in nasal ailment treatment
and subject-specific prognosis, and can contribute to the development of non-invasive
personalized therapeutics and treatment strategies. Preliminary results pertaining to
this work have featured at the American Physical Society (APS) – Division of Fluid Dy-
namics Annual Meetings17,18 and at the International Society for Aerosols in Medicine
(ISAM) Congress.19,20
2. Methods
2.1. Anatomic reconstructions
We have incorporated de-identified computed tomography (CT) data from three pre-
surgery chronic rhinosinusitis (CRS) patients; under approval with exempt status from
the Institutional Review Board (IRB) at the University of North Carolina at Chapel
Hill. Patient 1 was a 41 years-old Caucasian male (body weight 88 kgs, body mass index
25.3); patient 2 was a 70 years-old Caucasian male (body weight 67.5 kgs, body mass
index 24.8); and patient 3 was a 24 years-old Caucasian female (body weight 93.1 kgs,
body mass index 32.6). Medical-grade CT scans of the subjects’ nasal airways were used
to re-construct digital airway models through thresholding of the image radiodensity,
at a typical delineation range of -1024 to -300 Hounsfield units for airspace.10,21 As
part of that process, the DICOM (Digital Imaging and Communications in Medicine)
files for each subject were imported to the image processing software Mimics 18.0
(MaterializeTM, Plymouth, Michigan). For this study, we subsequently considered each
side of the in silico models as a distinct nasal passage model, while studying the spray
transport properties on that side: (a) patient 1’s right side was the nasal passage model
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1 (NPM1) and his left side was nasal passage model 2 (NPM2); (b) patient 2’s left side
was nasal passage model 3 (NPM3); and (c) patient 3’s right side was nasal passage
model 4 (NPM4) and her left side was nasal passage model 5 (NPM5).
To prepare the in silico anatomic models for numerical simulation of the inhaled
airflow and the sprayed particle transport therein, the airway volume was meshed and
segregated into minute volume elements. The meshing was implemented by importing
the Mimics-output in STL (stereolithography) file format to ICEM-CFD (ANSYSTM,
Canonsburg, Pennsylvania). As per established protocol,10,22 each computational grid
comprised approximately 4 million unstructured, graded tetrahedral elements; along
with four prism layers of 0.1-mm thickness extruded at the airway-tissue boundary with
a height ratio of 1.
2.2. Inspiratory airflow and sprayed particle transport simulations
Laminar steady-state models work as a reasonable approximation while modeling
comfortable resting to moderate breathing; see e.g.8,23–26 Furthermore, with our
simulations focusing on a single cycle of inspiration, steady state flow conditions were
adopted as a feasible estimate for resting breathing. Based on the principle of mass
conservation (continuity), and assuming that the airflow density stays unchaged over
time (incompressibility), we have
∇ · u = 0. (1)
Here u is the velocity field of the inspired air. Conservation of linear momentum under
steady state flow conditions would lead to the modified Navier-Stokes equations, which
are
ρ (u · ∇)u = −∇p+ µ∇2u + ρb. (2)
Here ρ = 1.204 kg/m3 represents the density of air, µ = 1.825 × 10−5 kg/m.s is
air’s dynamic viscosity, p is the pressure in the airway, and b stands for other body
accelerations resulting from gravity, inertia etc. To simulate the airflow, Equations (1)
and (2) were numerically solved through a finite volume approach, in the inspiratory
direction. The computational scheme employed a segregated solver, with SIMPLEC
pressure-velocity coupling and second-order upwind spatial discretization. Solution
convergence was obtained by minimizing the residuals (mass continuity∼ 10−2, velocity
components∼ 10−4), and through stabilizing the mass flow rate and the static outlet
pressure at the nasopharynx of the digital models. A typical simulation convergence
run-time with 5000 iterations clocked approximately 10 hours, for 4-processor based
parallel computations run at 4.00 GHz speed.
The numerical solution implemented the following set of boundary conditions: (1)
zero velocity at the airway-tissue interface i.e. at the tissue surface (no slip at the
walls, along with “trap” boundary conditions for particle tracking); (2) zero pressure
at nostril planes, which were the pressure-inlet zones in the simulations (with “reflect”
boundary conditions to re-direct escaping particles back into the airspace); and (3)
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a negative outlet pressure (with “escape” boundary conditions for particle tracking)
proportionate to the inhalation airflow rate estimated from subject-specific allometric
scaling: V˙ = 1.36M0.44 for males (while sitting awake) and V˙ = 1.89M0.32 for females
(while sitting awake). These scaling laws have been derived27 for a healthy cohort,
with V˙ as the minute volume in liters per minute and M as the subject’s body mass
in kilograms. The relations were deemed applicable for the current subjects based on
congruity of breathing patterns between CRS patients without nasal polyps and non-
symptomatic healthy individuals.
After simulating the airflow, sprayed particle transport was tracked through discrete
phase particle transport simulations in the ambient airflow, and the corresponding
Lagrangian tracking estimated the localized deposition along the airway walls (with
trap boundary conditions). Post-processing of the simulated data laid out the spatial
deposition trends, which were then tallied against the physical observations. The
simulations utilized a Discrete Phase Model (DPM), in which Lagrangian particle
tracking obtained the individual trajectories by numerically integrating the particle
transport equations:28
dup
dt
= FD(u− up) + g
(
1− ρ
ρp
)
+ FB. (3)
The parameters here include up, which represents the particle velocity; along with u as
the airflow field velocity, ρ and ρp respectively as the air and particle densities, g as the
gravitational acceleration, FB as any other additional body forces per unit particle mass
(as for example, Saffman lift force that is exerted by a typical flow-shear field on small
particulates transverse to the airflow direction), and FD(u−up) quantifies the drag force
contribution per unit particle mass.
Mean particle time step was evaluated to be of the order 10−5 s, with the
minimum and maximum limits for the adaptive step-size being ∼ 10−10 s and ∼ 10−3
s, respectively. Also note that the solution scheme posits the particulate droplets to be
large enough so as to ignore any possible Brownian motion effects on their dynamics.
TSPD in the OMC and the sinuses were evaluated in terms of the deposited mass
fraction percentage (∆MF ) , which was computed as ∆MF = 100×
(
Wtarget/WS
)
; with
Wtarget being the net weight of the particulate droplets deposited in the OMC and the
sinus cavities, and WS being the weight of one spray shot.
2.3. 3D printing and physical experiments
To check the reliability of numerically predicted topical deposition vis-à-vis physical
experiments, we generated 3D-printed solid models of two subject airways, made from
the stereolithograohy material Watershed® (DSM Somos®, Elgin, Illinois). Post-
digitization, the printing job was sub-contracted to the ProtoLabs (Maple Plain,
Minnesota). See Figure 2(a)-(c) for representative pictures of the digitized model and
the corresponding 3D replicate.
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Figure 2: (a) In silico model: CT-based digital reconstruction. Panels (b) and (c) show the solid 3D-printed replicate
of the digital model. Note that the solid models comprise a soft outer nose to mimic the pliability of a real nose and
posterior hard plastic part. The two components of the 3D print fit snugly together. Panels (d) and (e) depict the spray
experimental setup for in vitro measurement of sprayed deposits in anatomic solid models.
2.3.1. Recording deposits through gamma scintigraphy: Topical deposition was tracked
through in vitro measurements in 3D-printed solid anatomic replicates. To ensure that
the spray axis orientation and nozzle location align with the corresponding simulated
spray parameters, we used an aiming slot inserted at the nostril. The spray bottle was
fitted into the slot, while administering the nasal spray via hand-pumping. Note that
for each sample test, a bottle of commercial nasal spray Nasacort™ was labeled with
mildly radioactive Technetium (Tc99m). A compressor setup simulated the weight-
based inhalation airflow through the model (assuming open nostrils), at the time of
dispensing the spray shots. The corresponding setup is shown on Fig. 2(d)-(e). The
topical deposition was proportional to the radioactive signals emitted from the spray
solution traces that had deposited inside the solid model and was quantifiable through
image-processing of the scintigraphy visuals, collected using a 2D gamma camera. The
images were processed in ImageJ29 by constructing a region of interest (ROI) referenced
to fixed Americium sources on the solid model.
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Figure 3: Panels (a), (b), and (c) depict the gridline schematic used to extract the deposition fractions from the gamma
scintigraphy-based quantification of the sprayed deposits in the solid replicates. The models are segragated into 3 sets of
compartments: sagittal columns, sagittal rows, and front columns. Panel (d) shows the perturbation of the base gridline
by 1 pixel. Representative Technetium signals are in panel (e). Note: in regards to the axis system, the circle with solid
dot implies out-of-plane direction from this page, the circle with cross signifies into-the-plane of this page.
2.3.2. Model segmentation for comparison with numerical data: To facilitate
comparison between the numerical data on particle deposition along the internal walls
of a digital model and the physical observation of gamma scintigraphy signals, we
segregated two of the test models, NPM1 and NPM2, into virtual segments oriented
along three different directions. Figure 3 lays out the Cartesian coordinate directions of
the 3D space. X was in the sagittal direction from left to right of the nasal model, Y was
directed axially from inferior to superior side of the model, and Z was in the front-to-
back coronal direction relative to the model. The virtual segments were oriented along
the XY, YZ, and ZX planes. Parallel to the XY coronal plane, the models contained 12
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segments (named, C12 – C1 ⇒ sagittal columns); there were 9 compartments (C1 – C9
⇒ front columns) parallel to the YZ sagittal plane, and there were 12 compartments
(R1 – R12 ⇒ sagittal rows) parallel to the ZX axial plane. Refer to Figure 3 for
the details on the compartmental orientation. For each compartment, the particulate
deposition fractions predicted from the computational simulations were compared with
the deposition fractions measured based on gamma signals of the deposited particulates
in the corresponding compartment in the solid model. The latter was obtained by
superimposing the compartmental grid on the radio-images and then extracting the
signal from each virtual compartment.
2.4. Parameters for the simulated sprayshot
Nasacort™(generic name: Triamcinolone Acetonide), a commonly prescribed and
commercially available nasal spray, was selected for this study. Four units of
Nasacort™ were tested at Next Breath, LLC (Baltimore, MD, USA) to check for the
in vitro spray performance. Corresponding plume geometry was analysed through a
SprayVIEW® NOSP, which is a non-impaction laser sheet-based instrument. Averaged
spray half-cone angle was estimated at 27.93◦, and the droplet sizes followed a log-
normal distribution. With the droplet diameter as x, the particle size distribution can
be framed as a probability density function of the form:
f(x) =
1√
2pix lnσg
exp
[
−(lnx− lnx50)
2
2(lnσg)2
]
. (4)
Here, x50 = 43.81 µm is the count median diameter (alternatively, the geometric
mean diameter30) and σg = 1.994 is the geometric standard deviation. The latter
quantifies the span of the particle size data. Note that the mean spray exit velocity from
the nozzle was estimated to be 18.5 m/s, based on phase doppler anemometry-based
measurements.31 While simulating the particle trajectories, we assumed typical solid-
cone type injections and tracked the transport for 1 mg of spray shot while doing the
experimental comparisons (since we compared the relative deposition fractions without
knowing the exact quantity of particulate mass sprayed in the physical experiments) and
95.0306 mg (which is the experimentally determined spray shot quantity for Nasacort™,
as tested by Next Breath, LLC) while comparing the TSPD for the LoS and the CU
protocols in each model.
2.5. Identification of target site and spray positioning parameters
2.5.1. Effect of airflow on particle trajectories: Inertial motion of a particle is linearly
proportional to its mass, and hence is exponentially proportional to the particle diameter
to a cubic power. Consequently, for bigger particles, their inertial motion persists longer
before being taken over by the ambient airflow. Figure 4(a) tracks the trajectory of a
representative 5µ particle. The red circle marks the location where the inertial motion of
the particle got overwhelmed by the ambient flow, beyond which the particle trajectory is
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Figure 4: Comparison of trajectories of a representative 5µ particle and a representative 25µ particle in a sample
sinonasal airspace. In panel (a), the smaller particle has a weaker inertial motion and the ambient airflow streamline
takes over its motion much earlier than that in case of a heavier particle like the one in panel (b), where the inertial motion
of the 25µ particle persists longer. The small red circle in (a) depicts the point where the inertial motion gets overwhelmed
by the fluid streamline. Evidently, owing to smaller inertia, the particles with smaller diameters get predominated by the
airflow streamlines earlier than the bigger particles. This results in a better penetration and spread of sprayed particles
in the nasal airspace, as shown in panel (c). On the contrary, spray shots with exclusive share of bigger particles (e.g. >
100µ here) tend to follow their initial inertial trajectories, without much effect of the airflow streamlines on their paths,
and deposit along the anterior walls of the nasal airspace, as depicted in panel (d). Note: These images were created
using FieldView, as provided by Intelligent Light through its University Partners Program.
same as the airflow streamline on which it was embedded at the red circle location. Note
the contrasting 25µ particle trajectory in Figure 4(b), where the inertial motion persists
longer. The phenomenon has a significant impact on the eventual drug deposition along
the walls. The bigger particles (>100µ) show a greater propensity to hit the anterior
walls directly because of their stronger inertial motion, while spray shots with smaller
particle sizes do a better job at penetrating further into the airspace; see e.g. Figure 4(c)-
(d). So, to ensure that the bigger particles also reach the target sites, we argue that
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it would be conducive to actually utilize their inertial motion and have most of those
particles directed towards the target when they exit the spray nozzle. This can be
achieved by orienting the spray axis towards the intended anatomic target.
2.5.2. Current use instructions: There are ambiguities on the current protocol to use
nasal spray devices. Different commercial sprayers often offer somewhat contrasting
recommendations. However, there is a common agreement (see Figure 5(a)) that the
patient should incline their head forward while applying the spray. There is also a clinical
recommendation of not having the spray directed straight towards the septum. We have
adopted these two features in our standardization of “Current Use” (CU) protocol for
topical sprays. The digital models were inclined forward by an angle of 22.5◦, and the
vertically upright spray axis was closer to the lateral nasal wall, at one-third of the
distance between the lateral side and septal wall. Also, the spray bottle penetrates
into the airspace by a distance of 5 mm, inspired by the package recommendations of
commercial sprayers for a “shallow” insertion into the nose. Figure 5(b) lays out the
schematics of the current use protocol for this study.
2.5.3. Proposing alternate use criteria – Line of sight: All the sinuses drain into the
ostiomeatal complex (OMC), it being the main mucociliary drainage pathway and air-
flow exchange corridor between the airway and the adjoining sinus cavities. To ensure
that as many drug particulates reach the sinus chambers and their vicinity as would
be possible, we hypothesize that the spray axis should be directed straight towards the
OMC. This is supported by our observation of the effect of airflow physics on particle
trajectories (see discussion in Section 2.5.1). If the spray axis hits the OMC directly,
the chances that the larger particles will deposit there is higher. In this study, we refer
to this usage protocol as “Line of Sight” (LoS) use. Like the CU protocol, the LoS usage
(b)
(c)
- Lean forward a little
- Bottle upright 
         in one hand
(a)
δ/3
δ
22.5◦
Figure 5: (a) Sample pictorial instructions of nasal spray usage, available with commercial spray medication. Panels
(b) and (c) depict the protocol used in the numerical simulations for the CU spray orientation. Note that δ is the linear
distance between lateral wall and septum (the “mid-wall” in the nose, separating right and left airways) at 5-mm insertion
depth into the nose. The model “head” is reclined forward by 22.5◦. The dashed line represents the spray nozzle axis.
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(c)
(d)
Clinically important target sites for drug delivery
Frontal sinuses
Ethmoid sinuses
Semi - transparent sagittal view
Maxillary sinuses
Frontal sinuses
Semi - transparent axial view
Ostiomeatal complex
Maxillary sinus
Ostiomeatal
complex
(a) (b)
Sphenoid
Line of sight (LoS)
Spray axis to be aligned with the LoS in the 
proposed protocol
Figure 6: (a) Location of the main target site OMC, which acts as the mucociliary drainage pathway for the sinuses.
(b) Orientation of the “line of sight” (LoS) in NPM1. (c) Inspection of the LoS field-of-view from outside the nostril, in
a 3D-printed replicate made of soft plastic, that imitates the pliability of a real nose. On panel (d), the encircled blue
sliver marks the estimated location of the OMC.
also had the sprayer inserted at a depth of 5-mm into the nasal airspace. Representative
LoS orientation is shown in Figure 6.
3. Results
3.1. Comparison between CU and LoS spray usage protocols
LoS was found to be consistently better than the CU spray placement protocol, while
targeting the OMC and the sinus cavities for drug delivery. Table 1 lists the deposition
fraction percentages for each spray release condition in the 5 airway models (NPM1
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Table 1: Numerical prediction of targeted drug delivery from the CU protocol and the LoS.
Current Use (CU) Line of Sight (LoS)
Standard Deviation Mean Standard Deviation Mean
CU True Direction 0.88039 LoS True Direction 6.80497
0.46718 2.18483
0.44068 1.45414
0.58588 -
1.43778 2.89316
0.74409 1.57240
1.90422 1.57117
1.78006 2.81373
NPM1 Varying Peripheral
Points
0.98035
0.55461 1.02452 Varying Peripheral
Points
5.05763
1.92265 3.04401
CU True Direction 0.72616 LoS True Direction 6.00276
1.46264 2.91547
1.73342 1.36599
1.16387 -
0.56755 -
0.30213 1.30428
0.21316 2.41414
0.43108 2.52520
NPM2 Varying Peripheral
Points
0.85030
0.52752 0.82781 Varying Peripheral
Points
2.13272
1.58683 2.66579
CU True Direction 0.78580 LoS True Direction 12.44740
0.29675 3.95902
0.90962 2.35241
1.60885 1.98923
1.77025 2.07738
1.34794 1.99407
0.72918 -
0.29223 2.25115
NPM3 Varying Peripheral
Points
0.13509
0.59325 0.87508 Varying Peripheral
Points
2.96062
3.80595 3.96859
CU True Direction 0.48625 LoS True Direction 3.05041
0.91750 -
1.09860 -
0.84981 0.67269
0.45243 1.23603
0.17953 1.23148
0.12741 0.52666
0.21121 0.42972
NPM4 Varying Peripheral
Points
0.39559
0.35142 0.52426 Varying Peripheral
Points
-
0.97474 1.19116
CU True Direction 2.03183 LoS True Direction 3.63875
1.03519 2.86283
1.67774 3.24769
1.10419 2.46012
0.44269 1.06469
0.19756 0.70718
0.30772 0.59539
1.21377 0.62456
NPM5 Varying Peripheral
Points
1.90084
0.68326 1.10128 Varying Peripheral
Points
0.94140
1.24231 1.79362
The numbers are the deposition mass fraction percentages in the Sinus + OMC region, for each spray shot (95.0306 mg) of Nasacort.
The ‘-’ entries imply that the corresponding peripheral spray release locations were actually outside the digital internal nasal airspace.
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Figure 7: Comparison of the simulated spray deposits from the CU and LoS protocols. The yellow bar represents the
TSPD for true CU spray orientation, and the blue bar represents the true LoS spray orientation. The gray bars are
the predicted deposits when the true directions were perturbed by 1 mm. Panels (a)–(e) are the results for 5 different
airway models: Nasal Passage Model 1 (NPM1), Nasal Passage Model 2 (NPM2), Nasal Passage Model 3 (NPM3), Nasal
Passage Model 4 (NPM4), and Nasal Passage Model 5 (NPM5). The panel (f) shows the comparison between a 0.5-mm
perturbation (on the left) with respect to a 1-mm perturbation (on the right) from the true LoS orientation in NPM1.
For each perturbation, additional peripheral directions are considered, around the corresponding true direction. Inset:
Representative varying peripheral directions for the spray axis orientation.
– NPM5). For a graphical interpretation, we have plotted the same information on
Figure 7. Overall, the deposition fraction for the LoS was on an average 8.0-fold higher
than the CU deposition fraction, with the corresponding subject-specific improvement
range being 1.8 – 15.8 folds for the five test models. The improvement does decay
when the peripheral spray directions are compared, to assess the robustness of the LoS
protocol over CU. Note that the peripheral directions for CU initiate 1 mm away on
the nostril plane and are parallel to the true CU direction, and for LoS, its peripheral
directions are obtained by connecting the base of the true LoS direction on the nostril
plane and the points 1 mm away on the projection of the OMC on the view-plane for
best-possible OMC sighting from outside the nostril. Considering the varying peripheral
directions around the true LoS and CU, the LoS set registered a mean 2.9-fold increase
in TSPD, with the corresponding subject-specific improvement range being 1.6 – 4.5
folds.
3.1.1. Statistical tests – on improvements achieved by the revised strategy for spray use:
LOS was compared to CU using a paired study design with the data from the five test
Nasal spray usage 14
models (NPM1 – NPM5). Table 2 lays out the computed numbers. For each of the five
nostril models the outcomes were percentage of deposition in OMC plus sinuses for the
CU direction as well as the LoS direction. The percentage of deposition for the CU and
LoS directions from the same nostril were treated as paired observations for a paired
t-test to check the hypothesis that the percentage of deposition is the same for CU and
LoS. Because of the low number of observations, a paired Wilcoxon signed rank test was
also used as a robustness check. In order to study how spatial variation might affect
the difference between CU and LoS, three different ways of calculating the percentage
of deposition were implemented. The first was using the average deposition from the
true LoS and CU directions. The second was by averaging the simulations from the
true CU and LoS directions, along with the TSPD for 5 – 8 spray release parameters
obtained by perturbing the respective true directions. The third was by averaging just
the simulations from the release points perturbed from the true LoS directions. This
allowed us to see if any improvement from using LoS instead of CU was robust to slight
spatial variations. The results show that calculating percentage of deposition using just
the true direction LoS results in an average increase deposition of 5.4 percentage points
relative to current use (6.39-%vs.-0.98%). This difference is significant at the 0.05 level
with a p-value from the paired t-test of 0.04. The paired Wilcoxon signed-rank test
has a p-value of 0.06, which is the lowest possible p-value for the Wilcoxon signed-rank
test given only five pairs of data. When calculating the percentage of deposition using
true direction as well as the peripheral perturbation spray release points, LoS has an
increased deposition of 1.62 percentage points relative to CU (2.49%-vs.-0.87%). The p-
value for this difference is 0.02 using the paired t-test and 0.06 using the Wilcoxon signed
rank test. When calculating the percentage of deposition using just the spray release
points obtained by perturbing from the true direction, LoS has an increased deposition
of 1.05 percentage points relative to current use (1.90%-vs.-0.86%). The p-value for this
difference is 0.02 using the paired t-test and 0.06 using the Wilcoxon signed rank test.
This shows strong evidence that LoS leads to higher percentage of deposition in the
OMC and sinuses compared to CU. The estimated difference is largest when using just
the true directions, but the difference is still statistically significant even while using the
release points obtained by perturbing the true directions by 1 mm. The p-value from
the paired t-test is actually lower when the TSPD from just the perturbed points are
considered, owing to the reduced variance for the estimated difference. For all three
ways of estimating the percentage of deposition, the paired Wilcoxon signed-rank test
has a p-value of 0.06. This indicates that the LoS has higher deposition for all five
nostril models because 0.06 is the lowest possible p-value when having only five pairs of
data.
3.2. Gamma scintigraphy recordings
Intra-nasal topical delivery was tracked through in vitro examination of the mildly
radioactive spray deposits in the 3D-printed solid models. Signals emitted from the
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Table 2: Statistical comparison between CU and LoS.
LoS
mean
CU
mean
Estimated
Difference
CI
for difference
T-Test
p-value
(two sided)
T-Test
p-value
(one sided)
Wilcoxon
signed-rank
p-value (two sided)
Wilcoxon
signed-rank
p-value (one-sided)
True Direction 6.39 0.98 5.11 (0.95, 9.27) 0.03 0.01 0.06 0.03
Avg. of varying points,
incl. true direction
2.49 0.87 1.62 (0.45, 2.78) 0.02 0.01 0.06 0.03
Avg. of varying points,
excl. true direction
1.91 0.86 1.05 (0.32, 1.78) 0.02 0.01 0.06 0.03
Note: Compared measures are based on % deposition in OMC + Sinuses, based on 5 different airway models. ‘CI’ implies confidence interval.
Table 3: Comparison between the compartmental data from numerical simulations and physical experiments
Pearson’s rank correlation
in Nasal Passage Model 1
Pearson’s rank correlation
in Nasal Passage Model 2
Zero
shift
Zero
shift
CI
Neg.
shift
Neg.
shift
CI
Pos.
shift
Pos.
shift
CI
Mean
Zero
shift
Zero
shift
CI
Neg.
shift
Neg.
shift
CI
Pos.
shift
Pos.
shift
CI
Mean
Sagittal
columns
0.96 (0.61, 0.99) 0.85 (0.75, 1.00) 0.97 (0.79, 1.00) 0.93 0.98 (0.94, 1.00) 0.85 (0.75, 1.00) 0.97 (0.80, 1.00) 0.93
Sagittal
rows
0.95 (0.49, 0.99) 0.71 (0.48, 1.00) 0.91 (0.67, 1.00) 0.86 0.88 0.75, 1.00) 0.71 (0.55, 1.00) 0.91 (0.70, 1.00) 0.83
Front
columns
0.95 (0.89, 1.00) 0.93 (0.90, 1.00) 0.96 (0.40, 1.00) 0.95 0.96 (0.93, 1.00) 0.93 (0.90, 1.00) 0.96 (0.42, 1.00) 0.95
Kendall’s rank correlation
in Nasal Passage Model 1
Kendall’s rank correlation
in Nasal Passage Model 2
Zero
shift
Zero
shift
CI
Neg.
shift
Neg.
shift
CI
Pos.
shift
Pos.
shift
CI
Mean
Zero
shift
Zero
shift
CI
Neg.
shift
Neg.
shift
CI
Pos.
shift
Pos.
shift
CI
Mean
Sagittal
columns
0.71 (0.32, 0.95) 0.79 (0.52, 0.97) 0.91 (0.67, 1.00) 0.80 0.78 (0.41, 1.00) 0.79 (0.54, 0.97) 0.91 (0.68, 1.00) 0.83
Sagittal
rows
0.60 (0.11, 0.94) 0.79 (0.56, 0.96) 0.85 (0.53, 0.98) 0.75 0.64 (0.23, 0.93) 0.79 (0.56, 0.96) 0.85 (0.53, 1.00) 0.76
Front
columns
0.78 (0.34, 0.97) 0.85 (0.63, 0.99) 0.73 (0.41, 0.97) 0.79 0.72 (0.35, 0.96) 0.85 (0.63, 0.99) 0.73 (0.41, 0.97) 0.77
Note: Neg. shift = negative 1 pixel shift from base, Pos. shift = positive 1 pixel shift from base, CI = confidence interval.
settled solution traces along the airway walls were subjected to image processing
analysis. The spray signals were assigned to compartments by superimposing the
previously described grid (see Section 2.3.2) on the radio-image. In order to align
the grid on the image in a manner consistent with the virtual model, three inset discs
were incorporated as reference points on the outer surface of the virtual and 3D-printed
models. Technetium spiked solution was applied to these reference points on the 3D-
model and a radio-image was recorded. Image processing was performed to align the
emitted visual signals with similar reference regions within the superimposed grid. This
was done via manual visualization to achieve a best fit of signal intensity within reference
regions. The grid compartment planes positioned using this visual best-fit manner were
designated as “reference planes”. Given the nature of the radioactive signals and the
resolution of the radio-image, some signal intensity resided outside of reference regions
even while using best-fit practices. A reasonable fit could be obtained by shifting the
image one pixel in either direction. In order to account for this variation, alternative
Nasal spray usage 16
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
C12 C11 C10 C9 C8 C7 C6 C5 C4 C3 C2 C1
-Shi� +Shi� Experimental Reference
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
R12 R11 R10 R9 R8 R7 R6 R5 R4 R3 R2 R1
-Shi� +Shi� Experimental Reference
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
C9 C8 C7 C6 C5 C4 C3 C2 C1
-Shi� +Shi� Experimental Reference
(a) Nasal Passage Model 1 (b) Nasal Passage Model 2
-10.00%
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
C12 C11 C10 C9 C8 C7 C6 C5 C4 C3 C2 C1
-Shi� +Shi� Experimental Reference
-10.00%
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
R12 R11 R10 R9 R8 R7 R6 R5 R4 R3 R2 R1
-Shi� +Shi� Experimental Reference
0.00%
20.00%
40.00%
60.00%
80.00%
100.00%
C9 C8 C7 C6 C5 C4 C3 C2 C1
-Shi� +Shi� Experimental Reference
Sagittal columns
Front columns
Sagittal rows
Sagittal columns
Front columns
Sagittal rows
Figure 8: (a) Comparison of the numerically simulated compartmental findings in Nasal Passage Model 1, with respect
to the gamma scintigraphy recordings from the corresponding 3D-printed replicate. (b) Comparison of the numerically
simulated compartmental findings in Nasal Passage Model 2, with respect to the gamma scintigraphy recordings from
the corresponding 3D-printed replicate. Note that in order to focus on the OMC + sinus deposits, the data (plotted
above) left out the deposits in the anterior nose (from both the CFD and physical tests), in order to negate out the bright
radiation signal coming from that zone in the experimental deposits.
plane positions (see Figure 3(d)) were created by shifting the reference planes one
pixel in the positive and negative axes for each set of Cartesian planes, with one pixel
corresponding to a distance of 2.38 mm in the virtual and 3D models. These three
sets of compartment planes were positioned in the virtual model software using the
measured distances from the reference regions. The corresponding Cartesian coordinates
of these planes were used to assign particle deposition locations from the computational
simulations to grid compartments for comparison with the in vitro model.
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3.3. Comparison of the simulated predictions with physical experiments
Figure 8 compares the numerical predictions with corresponding physical spray experi-
ments, in NPM1 and NPM2. While the compartmental deposits present a similar trend
in each of sagittal columns, sagittal rows, and front columns; we conducted some sta-
tistical tests to verify the homogeneity between the two sets of data, as a means to
establishing the reliability of the computational findings. Table 3 gives the Pearson and
Kendall’s correlation between the numerical and experimental models for the average
deposition fraction for NPM1 and NPM2 for the LoS protocol. The confidence intervals
are based on 1000 bootstrap samples instead of asymptotic approximations because of
the relatively small sample size. Based on the output we can see that the Pearson cor-
relation is consistently very high while the Kendall’s correlation is not as high. While
the Kendall’s correlation is frequently thought to be more robust to outliers, particu-
larly for small sample sizes like this data set; in this instance the Pearson correlation
is likely more illustrative. This is because the Pearson correlation is able to show that
for the most part the magnitudes of the estimates are the same between the numerical
and experimental models. In general, there is a strong linear relationship between the
percent of deposition prediction from the numerical model and the corresponding phys-
ical measurements in the experimental model. The lower Kendall’s correlation (overall
mean measure 0.78) is largely due to regions where both the numerical and experimen-
tal models had very low average deposition but the exact rank of these regions changed
quite a bit between the two. Note that this does not necessarily indicate a poor perform-
ing numerical model. However, the very high Pearson correlation (overall mean measure
0.91) does indicate that the numeric model performs well for the considered test models.
4. Discussion
CFD-recommended revised nasal spray usage defined by the LoS protocol was found to
significantly increase topical drug delivery at targeted sinonasal sites, in comparison to
current use conditions. The work is expected to develop instructions and specifications
for improved use of topical sprays. This information has the potential to radically
improve the treatment paradigm for sinonasal ailments, through ascertaining LoS in
individual subjects via endoscopy tests conducted in the clinic itself, and to help guide
treatment decision-making and patient instruction in spray usage.
4.1. LoS scoring and the adaptibility of the findings in clinical practice
The LoS scores (see Table 4) were first determined observationally, based on the visibility
of the OMC site from outside the nostril of the in silico sinonasal reconstructions. The
range of scores ∈ [ 1, 4 ], with 4 being used when the LoS was most easy to ascertain.
Subjectively anecdotal as that scoring procedure might have been, it is similar to what
a practicing physician will do during a regular clinic visit to determine if a particular
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patient has a “line of sight” in her/his nasal anatomy. So, to establish the relevance
of the findings from this manuscript towards revisions of the therapeutic protocol for
sinonasal care, it was important to compare the observational LoS scores with more
objective determination techniques. Findings pertaining to the latter are also in Table 4,
along with how they compare with the observational scores. We calculated the surface
area of the nostril plane and the projected area of the OMC on the plane of the nostril.
Following this, we calculated the ratio of the projected area to the nostril area, as a
percentage. Scores of 4 were assigned if the ratio exceeded 6%, 3 if the ratio exceeded
4%, 2 if the ratio was more than 1.5%, and 1 if the ratio was greater than 0%. The
two techniques of scoring yielded very similar results, with the highest and lowest scores
respectively going to the same anatomic models. Pearson’s rank correlation for the two
sets of scores was 0.85. While a broader study, involving clinical trials, will be necessary
to revise therapeutic protocol for sinus drug delivery, the present results hence show the
promise for easy adaptability into clinical practice settings.
4.2. Caveats on the comparability of the experimental data with the numerical findings
The computational simulations assumed a laminar framework to mimic steady
breathing. However, it may be argued that even at steady breathing rates, the airflow
often depict transitional features like vortices, that emerge from the roll-up of shearing
fluid layers during the flow-structure interactions32,33 at the anatomic bends. Some of
these nuances are, in fact, hard to model without proper turbulence simulations.34,35
However, true as that may be, the effect of these flow artifacts on drug delivery has been
found to be insignificant through comparing laminar and turbulence simulation results,
e.g. see.10 On the other hand, if we ponder on the comparability of the numerical
data with the physical experiments, the in vitro techniques often present a series of
challenges. For example, after being deposited, the spray solution can move around
along the inner walls of the solid replicate. Such drip-off dynamics can often lead
to a flawed estimate of regional deposition in the spray experiments. Also, in the
gamma scintigraphy method of recording deposits, the radiation signal undergoes some
level of scattering and hence when we were trying to extract signals from each of the
compartments pertaining to the saggital columns, sagittal rows, and front columns;
there was always the possibility of the signal from one compartment contaminating the
Table 4: Comparison of the LoS scores, obtained observationally and through determining the surface area projection
of the targeted OMC on the nostril plane.
Observational
LoS score
Nostril SA
(mm2)
LoS SA
projection
(mm2)
LoS SA projection
as % of Nostril SA
SA-based
LoS score
Pearson’s correlation
between two sets
of scores
SA-based scoring
criteria
NPM1 4 103.9367 6.9209 6.66 % 4 >6 % 4
NPM2 3 83.3166 1.4370 1.72 % 2 >4 % 3
NPM3 3 67.1599 5.0085 7.46 % 4 >1.5 % 2
NPM4 2 109.9467 2.5846 2.35 % 2 >0 % 1
NPM5 1 104.1179 0.0904 0.09 % 1
0.850
SA ⇒ surface area
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signals at the neighboring compartments. To minimize this effect while carrying out
the comparisons, we left out the front anterior nose (the soft plastic anterior part in the
solid models), which had a bright radiation signal owing to the anterior deposits, from
both the experimental and numerical data.
4.3. Future implications and caveats
We should not ignore the caveat that this was a computational study with validation
from inanimate solid replicates. Also, not every patient will have a clear access to the
OMC, and hence will be without an LoS. For instance, in the current study, of the six
airway sides in the three study subjects, patient 2’s right side anatomy did not exhibit
an LoS.
This study is however, to the best of our knowledge, the first-of-its-kind to propose
an alternative easy-to-implement strategy that can significantly improve the intra-nasal
delivery of topical drugs at the diseased sites. The recommendations for using the line
of sight is user-friendly and has the potential to be smoothly incorporated into the nasal
standard-of-care. For probable revisions to the clinical regimen, we will need a broader
study with more subjects, along with a component for clinical trials to track patient re-
sponse. On a larger perspective, this study postulates how relatively simple engineering
analysis tools can revolutionize the prognosis and treatment of common ailments like
blocked nose.
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